A Study of PHN-012 in Patients With Advanced Solid Tumors

2025-523756-31-00 Protocol PHN-012-001 Human pharmacology (Phase I) - First administration to humans Ongoing, recruiting

Start 26 Mar 2026 · Status Ongoing, recruiting · 1 EU/EEA countries · 10 sites · Protocol PHN-012-001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruiting
Participants planned 165
Countries 1
Sites 10

Advanced Solid Tumors

Key facts

Sponsor
Pheon Therapeutics Limited
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
26 Mar 2026 → ongoing
Decision date (initial)
2026-03-06
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2025-523756-31-00
ClinicalTrials.gov
NCT07127874

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Advanced Solid Tumors

VersionLevelCodeTermSystem organ class
21.1 LLT 10065147 Malignant solid tumor 10029104
21.1 LLT 10065252 Solid tumor 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Pheon Therapeutics Limited

Sponsor organisation
Pheon Therapeutics Limited
Address
Innovation House, Innovation Way, Discovery Park Innovation Way Discovery Park
City
Sandwich
Postcode
CT13 9FF
Country
United Kingdom

Scientific contact point

Organisation
Pheon Therapeutics Limited
Contact name
Executive Director, Clinical Development

Public contact point

Organisation
Pheon Therapeutics Limited
Contact name
Executive Director, Clinical Development

Locations

1 EU/EEA country · 10 investigational sites

By country

CountryMS statusPlanned subjectsSites
Spain Ongoing, recruiting 50 10
Rest of world
United States, Korea, Republic of
115

Investigational sites

Spain

10 sites · Ongoing, recruiting
Hospital Universitario Ramon Y Cajal
Medical Oncology, Carretera Del Colmenar Viejo Km 9 100, Por El Pardo, Madrid
Hospital Universitario Fundacion Jimenez Diaz
Oncology, Avenida De Los Reyes Catolicos 2, 28040, Madrid
Hospital Hm Nou Delfos
Oncology, Avinguda De Vallcarca 151, 08023, Barcelona
Hospital Quironsalud Barcelona
Oncology, Placa D'alfonso Comin 5-7, 08023, Barcelona
Hospital Universitari Vall D Hebron
Oncology, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona
Clinica Universidad De Navarra
Oncology, Calle Marquesado De Santa Marta 1, 28027, Madrid
Hospital Clinico Universitario De Valencia
Oncology, Avenida Blasco Ibanez 17, 46010, Valencia
Fundacion Instituto Valenciano De Oncologia
Oncology, Calle De Gregorio Gea 3 1 A Planta, 46009, Valencia
Hospital Universitario Hm Sanchinarro
Centro Integral Oncológico Clara Campall (CIOCC) Phase I trials unit, Calle Ona 10, 28050, Madrid
Hospital General Universitario Gregorio Maranon
Oncology, Calle Del Doctor Esquerdo 46, 28007, Madrid

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Spain 2026-03-26 2026-03-31

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2026-01-12 Spain Acceptable
2026-03-05
2026-03-06